Table 3.
The risk of bladder cancer in CIDC patients and non-CIDC patients.
| Crude HR (95% C.I.) | p-value | Adjusted HR (95% C.I.) | p-value | |
|---|---|---|---|---|
| CIDC, yes vs. no | 5.73(4.93-6.66) | <0.0001 | 5.16(4.35-6.13) | <0.0001 |
| Comorbidity | ||||
| Hypertension | 1.14(0.96-1.34) | 0.1315 | 1.21(0.97-1.51) | 0.0982 |
| Hyperlipidemia | 0.90(0.70-1.17) | 0.4360 | 1.08(0.77-1.51) | 0.6646 |
| CKD | 3.49(1.02-11.93) | 0.0459 | 2.53(0.50-12.97) | 0.2646 |
| COPD | 0.86(0.65-1.14) | 0.2920 | 0.73(0.51-1.04) | 0.0800 |
| Liver disease | 0.90(0.62-1.29) | 0.5591 | 1.07(0.67-1.7) | 0.7806 |
| Complication | ||||
| BHP | 3.21(2.64-3.91) | <0.0001 | 1.92(1.50-2.45) | <0.0001 |
| UTI | 3.25(2.68-3.94) | <0.0001 | 1.02(0.79-1.32) | 0.8840 |
| Urinary Tract Stones | 4.60(3.02-7.00) | <0.0001 | 2.58(1.52-4.37) | 0.0004 |
* CIDC: chronic indwelling catheter; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; BPH: benign prostatic hyperplasia; UTI: urinary tract infections; HR: hazard ratio; CI: confidence interval.